In the UK, NICE has just approved Tarceva in non-small cell lung cancer (NSCLC) after Roche agreed to drop the price.
More details later.
Pharma Strategy Blog
Commentary and insights on Pharma & Biotech new product development with a focus on oncology and hematology
